theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

COVID-19

Yale   

Questions discussed in this category


Are there circumstances where you would recommend every 6 week dosing schedule for pembrolizumab monotherapy?
I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...
3 Answers available

How has COVID-19 altered your recommendations for invasive mediastinal staging for NSCLC?
Should staging and treatment decisions be made based on imaging alone?
2 Answers available

Should we consider deferring adjuvant chemotherapy for resected early-stage NSCLC in light of COVID-19?
If so, how long is too long to wait?
1 Answer available
689168166815

Related Topics in COVID-19

  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Oncology
  • Gastrointestinal Cancers
  • Genitourinary Cancers
  • Melanoma/Skin Cancer
  • Non-malignant Disease
  • Pediatric Hematology/Oncology

Copyright © 2025 theMednet
All Rights Reserved.